Anergis
Epalinges
About Anergis
Anergis, a clinical-stage biopharmaceutical company, discovers and develops allergy vaccines based on the technology of Contiguous Overlapping Peptides for ultra-fast desensitization. It offers vaccines against birch pollen, ragweed pollen, and house dust mite allergies. Francois Spertini founded Anergis in 2001. Its headquarters in Lausanne in Switzerland.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $49.0M
- Funding stage: Late Stage Venture
- Last round: Series C (Apr 2016)
- Website: anergis.ch
- Phone: 0041-216519223
Industries & Categories
Biotechnology, Health Care, Life Science, Medical, Personal Health
Social Profiles
Canonical: https://fsome.com/organization/anergis-107303 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.